{"id":"W2473317929","doi":"10.1200/jco.2015.33.3_suppl.512","title":"RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"ca_institutions":"Eli Lilly (Canada)","funders":"","keywords":"Medicine; FOLFIRI; Ramucirumab; Internal medicine; Clinical endpoint; Hazard ratio; Irinotecan; Progression-free survival; Phases of clinical research; KRAS; Oncology; Log-rank test; Gastroenterology; Colorectal cancer; Randomized controlled trial; Clinical trial; Proportional hazards model; Cancer; Chemotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002449594,0.002229298,0.003285808,0.0005335163,0.0005218156,0.001196908,0.001189384,0.001891936,0.005833721],"category_scores_gemma":[0.00188758,0.001145984,0.001393388,0.0004641535,0.001514972,0.001301206,0.0005557158,0.002907798,0.001231357],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007357155,"about_ca_system_score_gemma":0.001443282,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007077061,"about_ca_topic_score_gemma":0.001893833,"domain_scores_codex":[0.9991888,0.000481724,0.00003915962,0.0001248555,0.00005798223,0.0001073565],"domain_scores_gemma":[0.9989601,0.0002640834,0.000222007,0.0000816979,0.00006468249,0.0004074433],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9732732,0.01315652,0.0004040976,0.0002671109,0.0003770118,0.00003611666,0.00005086693,0.0003401941,0.003936841,0.00008681445,0.0004332943,0.007637931],"study_design_scores_gemma":[0.9228898,0.07519763,0.0007216153,0.00000750036,0.0002094847,0.00002042057,0.00001059887,0.0002780471,0.0003317992,0.00005871387,0.0002658613,0.000008551046],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9881787,0.001445224,0.0009751575,0.0004426118,0.0003580312,0.005910195,0.0008646919,0.0002026607,0.001622792],"genre_scores_gemma":[0.9836795,0.00154897,0.002283229,0.0009738082,0.0005848722,0.006683009,0.001208485,0.00003799473,0.00300007],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005833721,"threshold_uncertainty_score":0.01951569,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1348567628289724,"score_gpt":0.4327987403504687,"score_spread":0.2979419775214963,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}